Jessica Ailani, EAN 2021: Phase 3b CONQUER Trial Results
It was a great pleasure to meet with Jessica Ailani (MedStar Georgetown, Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, WA, USA) to discuss the impact of galcanezumab on migraine care in the phase 3b CONQUER trial.
The abstract entitled: ‘Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b trial’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
- What has been the impact of galcanezumab on migraine care? (0:15)
- What questions remain unanswered about the clinical utility of galcanezumab? (1:43)
- Could you briefly summarise the safety and efficacy findings from the CONQUER trial which you presented at the EAN congress? (4:49)
- What do you think will be the clinical impact of these findings? (6:08)
- Is there a subgroup of patients which were found to be most likely to benefit from galcanezumab? (7:31)
Disclosures: Jessica Ailani has received honoraria for independent consulting from Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, and Medscape; has ownership of stocks at CtrlM; is part of the Speakers Bureau (Honoraria for promotional speaking) at Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva; and provides editorial services (Honoraria) from Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, and SELF (medical reviewer). Jessica Ailani also receives clinical trial grants (Fees to Institution) from American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, and Zosano.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!